Skip to main content

Advertisement

SpringerLink
Log in

Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Nineteen patients with postmenopausal osteoporosis were treated with 200 u (15 nmol) synthetic salmon calcitonin (sCT) intranasally per day for 15 months. Six months after the start of the nasal administration of sCT, antibodies were recognized in 7, and after 15 months in 10 of the 19 patients studied. The half-maximal dilution of serum binding to 60 pmol/1 [125I] sCT (dilution-50) ranged from 2 to 490, and half-maximal inhibition of [125I]sCT binding (60 pmol/1) from 91 to 221 pmol/l sCT. In a cultured breast cancer cell line (T47D) cAMP production was stimulated by sCT (EC50 70 pmol/l). Stimulated cAMP production by sCT (50 pmol/1) was reduced to between 4% and 23% in the presence of serum from patients with antibody dilution-50 of [125I]sCT binding exceeding 32. In patients with lower titer antibodies cAMP production was only marginally suppressed. The values of patients with postmenopausal osteoporosis were in the range of those of earlier studied patients with Paget's disease and clinical resistance to sCT. There was a linear relation between the antibody dilution-50 and the serum dilution required for half-maximal inhibition of cAMP production (P<0.01). In conclusion, neutralizing antibodies to sCT may contribute to the decreased responsiveness of bone mineral loss during prolonged treatment with sCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gruber HE, Ivey JL, Baylink DJ et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33:295–303.

    PubMed  Google Scholar 

  2. Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985; 34:124–9.

    PubMed  Google Scholar 

  3. Gennari C, Chierichetti SM, Bigazzi S et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Cur Ther Res 1985; 38:455–64.

    Google Scholar 

  4. Mazzuoli GF, Passeri M, Gennari C et al. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study. Calcif Tissue Int 1986; 38:3–8.

    PubMed  Google Scholar 

  5. Reginster JY, Albert A, Lecart MP et al. 1-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987; ii:1481–3.

    Google Scholar 

  6. MacIntyre I, Whitehead MI, Banks LM, Stevenson JC, Wimalawansa SJ, Healy MJR. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; i:90O-2.

    Google Scholar 

  7. Civitelli R, Gonnelli S, Zacchei F et al. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. J Clin Invest 1988; 82:1268–74.

    PubMed  Google Scholar 

  8. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 1989; 299:477–9.

    Google Scholar 

  9. Resch H, Pietschmann P, Willvonseder R. Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures. Calcif Tissue Int 1989; 45:209–13.

    PubMed  Google Scholar 

  10. Rojanasathit S, Rosenberg E, Haddad JG Jr. Paget's bone disease: Response to human calcitonin in patients resistant to salmon calcitonin. Lancet 1974; ii:1412–15.

    Google Scholar 

  11. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 1980; 23:1148–53.

    PubMed  Google Scholar 

  12. Singer FR, Mills BG. Paget's disease of bone: Etiologic and therapeutic aspects. J Bone Min Res 1984; 2:394–421.

    Google Scholar 

  13. Lo Cascio V, Adami S, Galvanini G et al. Response of Paget's disease to human calcitonin in patients resistant to porcine calcitonin. J Endocrinol Invest 1984; 7:85–88.

    PubMed  Google Scholar 

  14. Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget's disease of bone. Arch Intern Med 1987; 147:1305–8.

    PubMed  Google Scholar 

  15. Muff R, Dambacher MA, Perrenoud A, Simon C, Fischer JA. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin. Am J Med 1990; 89:181–4.

    PubMed  Google Scholar 

  16. Levy F, Muff R, Dotti-Sigrist S, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab 1988; 67:541–5.

    PubMed  Google Scholar 

  17. Dietrich FM, Hunziker WH, Fischer JA. Synthetic human calcitonin: Analysis of antibodies obtained from various animal species and determination of immunoreactive hormone in human sera. Acta Endocrinol (Copenh) 1975; 80:465–86.

    PubMed  Google Scholar 

  18. Moran J, Hunziker W, Fischer JA. Calcitonin and calcium ionophores: Cyclic AMP responses in cells of a human lymphoid line. Proc Natl Acad Sci USA 1978; 75:3984–8.

    PubMed  Google Scholar 

  19. Born W, Dambacher MA, Meyrier A, Ardaillou R, Fischer JA. Parathyroid suppressibility in hyperparathyroidism due to chronic renal failure: Studies with autotransplanted parathyroid tissue. Clin Endocrinol 1982; 17:333–43.

    Google Scholar 

  20. Grauer A, Raue F, Schneider H-G, Frank-Raue K, Ziegler R. In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J Bone Min Res 1990; 5:387–91.

    Google Scholar 

  21. Haddad JG Jr, Caldwell JG. Calcitonin resistance: Clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins. J Clin Invest 1972; 51: 3133–41.

    PubMed  Google Scholar 

  22. DeRose J, Singer FR, Avramides A et al. Response of Paget's disease to porcine and salmon calcitonins: Effects of long-term treatment. Am J Med 1974; 56:858–66.

    PubMed  Google Scholar 

  23. Dietrich FM, Fischer JA, Bijvoet OLM. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol (Copenh) 1979; 92:468–76.

    PubMed  Google Scholar 

  24. Tashjian AH Jr, Wright DR, Ivey JL, Pont A. Calcitonin binding sites in bone: Relationships to biological response and 'escape'. Recent Prog Horm Res 1978; 34:285–334.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Orthopedic Surgery and Medicine, Research Laboratory for Calcium Metabolism, University of Zurich, Zurich, Switzerland

    R. Muff, M. A. Dambacher &  J. A. Fischer

Authors
  1. R. Muff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Dambacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muff, R., Dambacher, M.A. & Fischer, J.A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1, 72–75 (1991). https://doi.org/10.1007/BF01880446

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01880446

Keywords

Search

Navigation